Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study

被引：0

作者：

Dietrich, Sascha ^{[1
]}

Tilly, Herve ^{[2
,3
]}

Morschhauser, Franck ^{[4
]}

Sehn, Laurie H. ^{[5
,6
]}

Friedberg, Jonathan W. ^{[7
]}

Trneny, Marek ^{[8
]}

Sharman, Jeff ^{[9
]}

Herbaux, Charles ^{[10
]}

Burke, John M. ^{[11
]}

Matasar, Matthew ^{[12
]}

Rai, Shinya ^{[13
]}

Izutsu, Koji ^{[14
]}

Mehta-Shah, Neha ^{[15
]}

Oberic, Lucie ^{[16
]}

Chauchet, Adrien ^{[17
]}

Jurczak, Wojciech ^{[18
]}

Song, Yu Qin ^{[19
]}

Greil, Richard ^{[20
,21
]}

Mykhalska, Larysa ^{[22
]}

Bergua Burgues, Juan Miguel ^{[23
]}

Cheung, Matthew C. ^{[24
]}

Pinto, Antonio ^{[25
]}

Shin, Ho-Jin ^{[26
]}

Hapgood, Greg ^{[27
]}

Munhoz, Eduardo ^{[28
]}

Salles, Gilles ^{[12
]}

机构：

[1] Univ Klinikum Heideberg, Klin Hamatol Onkol Rheumatol, Heidelberg, Germany

[2] Ctr Henri Becquerel, Rouen, France

[3] Univ Rouen, Rouen, France

[4] Univ Lille, Grp Rech Formes Injectables & Technol Associees, CHU Lille, Lille, France

[5] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[6] Univ British Columbia, Vancouver, BC, Canada

[7] UR Med Wilmot Canc Ctr, Rochester, NY USA

[8] Charles Univ Prague, Gen Hosp, Fac Med 1, Prague, Czech Republic

[9] US Oncol, Willamette Valley Canc Inst, Eugene, OR USA

[10] CHU Montpellier, Montpellier, France

[11] US Oncol, Rocky Mt Canc Ctr, Aurora, CO USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY USA

[13] Kindai Univ, Fac Med, Osaka Sayama City, Japan

[14] Natl Canc Ctr, Tokyo, Japan

[15] Washington Univ, St Louis, MO USA

[16] Toulouse Oncopole, Inst Univ Canc, Toulouse, France

[17] CHRU Besancon, Dept Hematol, Besancon, France

[18] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[19] Peking Univ Canc Hosp, Beijing, Peoples R China

[20] Paracelsus Med Univ, Salzburg Canc Res Inst CCCIT, Salzburg, Austria

[21] Canc Cluster Salzburg, Salzburg, Austria

[22] Clin Hosp Feofaniya, Kiev, Ukraine

[23] Hosp San Pedro Alcantara, Caceres, Spain

[24] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[25] IRCCS, Hematol Oncol Stem Cell Transplantat Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy

[26] Pusan Natl Univ, Sch Med, Med Res Inst, Pusan Natl Univ Hosp, Busan, South Korea

[27] Princess Alexandra Hosp, Brisbane, Qld, Australia

[28] Hosp Erasto Gaertner, Curitiba, Parana, Brazil

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

891

引用

页码：165 / 165

页数：1

共 50 条

[21] A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007
David, Lavie
Muhit, Ozcan
Ewa, Paszkiewicz-Kozik
Eva, Gonzalez Barca
Min, Kim Tae
Benedetta, Puccini
Siruo, Wang
Rushdia, Yusuf
Patricia, Marinello
Seog, Kim Won
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S31 - S32
[22] A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma
Micallef, Ivana N. M.
Kahl, Brad S.
Maurer, Matthew J.
Dogan, Ahmet
Ansell, Stephen M.
Colgan, Joseph P.
Geyer, Susan
Inwards, David J.
White, William L.
Habermann, Thomas M.
CANCER, 2006, 107 (12) : 2826 - 2832
[23] Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma
Roschewski, Mark
Dunleavy, Kieron
Wilson, Wyndham H.
LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2428 - 2437
[24] Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
Micallef, I. N.
Maurer, M.
Nikcevich, D.
Cannon, M.
Moore, D.
Kurtin, P.
Schaefer, E.
Witzig, T.
ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
[25] Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
Forero-Torres, Andres
Kolibaba, Kathryn S.
Tilly, Herve
Salles, Gilles
Wang, Lijia
Lee, Calvin
Sharman, Jeffrey P.
BLOOD, 2017, 130
[26] A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
Micallef, I. N.
Maurer, M. J.
Nikcevich, D. A.
Cannon, M.
Moore, D. F., Jr.
Kurtin, P.
Witzig, T. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[27] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
Sawalha, Yazeed
Welkie, Rina Li
Krivenko, Anna
Hess, Brian
Sigmund, Audrey M.
Voorhees, Timothy
Hanel, Walter
Bond, David A.
Reneau, John C.
Epperla, Narendranath
Alinari, Lapo
Brammer, Jonathan E.
Christian, Beth
Baiocchi, Robert
Maddocks, Kami J.
BLOOD, 2023, 142
[28] POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
Tilly, Herve
Flowers, Christopher
Friedberg, Jonathan W.
Herbaux, Charles
Morschhauser, Franck
Sehn, Laurie Helen
Sharman, Jeff Porter
Trneny, Marek
Lee, Calvin
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituxamib) in first-line therapy of diffuse large B cell lymphoma (DLBCL): An interim analysis
Herbrecht, Raoul
Couban, Stephen
Weissinger, Florian
Gorbatchevsky, Igor
van der Jagt, Richard H.
BLOOD, 2007, 110 (11) : 1009A - 1010A
[30] Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model
Dong, Liangliang
Zhong, Wanfu
Chen, Ting
Zhao, Qiuling
Liu, Wenbin
Qiu, Xiuliang
Huang, Ruyi
Huang, Shengqiang
Xie, Ruixiang
Yang, Lin
BMJ OPEN, 2025, 15 (01):

← 1 2 3 4 5 →